Alibaba Health Information Technology stock
0241.HKHKSEAlibaba Health Information Technology Limited, HealthcareISIN BMG0171K1018
59Score 59 out of 100, Neutral
Price and trend
42 / 100
Price history
−50% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 27% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 62% below its 52-week high. Largest decline in 20 years: 94% (May 2007 to October 2008).
Chart figures for advanced users
- SMA 50$0.37
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$0.51
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.35
- The lowest closing price of the last twelve months.
- Resistance$0.99
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alibaba Health Information Technology Limited belongs to the Medical (Healthcare Information Services) industry (Hong Kong SAR China) and, with a market value of $6.02B, is number 6 of 24 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $5.14B (up 12% year on year) and earnings of $290.35M (up 35.2%).
- MEQIRI Score 59 out of 100 (Neutral): rank 273 of 702 in Healthcare, median 53.
Show more
- The P/E is 20.8 (Healthcare sector median 32.3, own median of recent years 47.3).
- Our model puts fair value at $1.00, with the price 63% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 35.5% a year since 2021.Growth 81
- Below fair valuePrice 63% below the fair value of $1.00.Valuation 83
- More cash than debtCash $1.57B, financial debt $8.93M.Stability 84
Weaknesses
- DilutionShare count up 22% since 2021.Capital allocation 49
- Share price fell sharplyDown 49% over the last 12 months.Momentum 24
Its standout strengths are stability and valuation, while technical analysis and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 60 to 59.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $0.71 and expensive above $1.66 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $1.41 (cash-flow model) and $0.58 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.5%. At 8.5% the fair value would be $0.87, at 6.5% it would be $1.19.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (32.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue rose 12% on the prior year. Revenue has grown strongly since 2007, at around 29% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 24%, operating 5%, net 6%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 1 Dec 2026in 18 days
- Last reported
- 14 May 2026EPS reported 0.07 (expected 0.06)above expectations
Analyst estimates
Earnings estimates have barely changed since 26 Oct 2026.
- Earnings per share
- 0.13+0.2%
- Revenue
- $6.56B+0.2%
- Earnings per share
- 0.15+0.2%
- Revenue
- $7.24B+0.2%
MEQIRI has stored the estimates since 26 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Sector comparison
702 rated companies in Healthcare
- This company
- 59
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- Tempus AITEM $13.46B45
- Hinge HealthHNGE $9.83B70
- HealthEquityHQY $8.52B71
- M32413.T $7.69B73
- DoximityDOCS $5.92B82
- Waystar HoldingWAY $5.41B60
- HeartflowHTFL $5.21B47
- Privia Health GroupPRVA $3.02B57
ETFs that hold Alibaba Health Information Technology
Held by 55 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 2.17% | 0.68% | €5.31M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 0.98% | 0.49% | €318.64M |
| Amundi MSCI China ESG Selection Extra UCITS ETF DistLHKG | 0.16% | 0.65% | €564.13M |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.14% | 0.30% | €132.6M |
| Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (C)AMEI | 0.13% | 0.25% | €2.64B |
| Deka MSCI China ex A Shares UCITS ETFEL46 | 0.10% | 0.65% | €73.86M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.10% | 0.60% | €31.52M |
| Deka MSCI Emerging Markets UCITS ETFEL40 | 0.09% | 0.40% | €304.94M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 17 Jan 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.